Product mentioned on podcasts
BPC-157
Mentioned on 4 episodes by 4 guests across our covered podcasts.
SignalCast may earn commission on purchases via these links.
Who mentioned it
“seven peptides—including BPC-157 and TB-500—are scheduled for re-legalization review in July 2025. BPC-157, for example, has no established LD-1 dose, meaning researchers cannot determine a quantity harmful to even 1% of test subjects, making it among the most well-tolerated compounds studied in animal models.”
Mentioned on: The Diary of a CEO“BPC-157, the flagship peptide in self-administration stacks, has a half-life measured in seconds after injection, leaving no pharmacological window to produce therapeutic effects.”
Mentioned on: a16z Podcast“Internal medicine physician Dr. Abud Bakri provides a clinical framework for understanding peptides, covering BPC-157's origins in Croatian gastric research, growth hormone secretagogues like tesamorelin and MK-677, the tripeptides EDR (pinealon) and GHK-copper”
Mentioned on: Huberman Lab“BPC-157 shows no recorded human fatalities but poses tumor vascularization risk, making short-term injury use a more defensible application than chronic systemic dosing.”
Mentioned on: a16z Podcast